Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer

Stock Information for Sesen Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.